TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05450926

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound-guided selective cervical nerve root block
Description: The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided selective cervical nerve root block
Description: The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
Study: NCT05565001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levcromakalim
Description: Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.
Study: NCT04531618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Exchange (EE)
Description: These sessions, conducted by a trained study staff member through Zoom, will involve storytelling and discussing emotional experiences with the baby, with prompts like sharing about the pregnancy or reactions to the baby's smiles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Newborn Care (NC)
Description: Newborn Care (NC) is a teaching curriculum designed to provide mothers with developmentally appropriate information about newborn care. The curriculum is adapted from previously studied literature that increased maternal knowledge about both medical and developmental concerns.
Study: NCT05368415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
Study: NCT05718323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200 mg orally once daily, until PD 300 mg once daily if body weight ≥77 kg and platelets ≥150 g/L, until PD
Study: NCT03616067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox® injection
Description: Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopoderm® patches arm
Description: Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear.
Study: NCT05409313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EBP training
Description: The EBP training program was modified by the 5A-steps EBP teaching model that which aimed to enhance nurses' EBP competencies and application. A 12-hours EBP training consisted of lectures, hand-on practice, group and individual consulting, group presentations and reflections, and disseminating findings to publish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDM training
Description: A 10-hour SDM training program included lecture 4 hours and workshops 6 hours, with focused on 3-talk model for SDM skills, 4-habit model for communication skill, and how to use Ottawa personal decision guide. Teaching strategies included lectures, clinical scenarios role play, and post-scenario debriefing. The major contents were SDM concepts and essential steps, SDM tools, strategies for the clinical implementation, the concept and purpose of choosing wisely campaign, and patient-centered communication skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SDM training
Description: A 10-hour SDM training program included lecture 4 hours and workshops 6 hours, with focused on 3-talk model for SDM skills, 4-habit model for communication skill, and how to use Ottawa personal decision guide. Teaching strategies included lectures, clinical scenarios role play, and post-scenario debriefing. The major contents were SDM concepts and essential steps, SDM tools, strategies for the clinical implementation, the concept and purpose of choosing wisely campaign, and patient-centered communication skills.
Study: NCT05213013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhaler treatment with the toy-type nebulizer and training on on the use of a nebulizer/mask
Description: The children (experimental group), will receive training and inhaler treatment with the toy-type nebulizer. The training topics is as follows:~* For effective nebulization, it should be ensured that the parts of the mask are assembled completely and correctly.~* The child should be in an upright sitting position during nebulization.~* During the procedure, normal breathing should be given into the mask.~* As the medicine is finished, a sizzling sound is heard from the device.~* After the nebula is over, the face should be washed and the mouth should be rinsed to remove the drug residues accumulated on the face and mouth.
Study: NCT04455698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Telegenetic Counseling by Phone
Description: Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor by Telephone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Telegenetic Counseling by Videoconferencing
Description: Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor using Videoconferencing Technology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Arm
Description: Participants in the usual care arm will receive usual care services depending on which referral method they choose and if they initiate services. After a 6 month status survey, if they have not had genetic services through usual care they will be offered services and re-randomized to ARM A/ARM B.
Study: NCT05654272

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Cardiac MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Cardiac MRI
Study: NCT05039177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered orally
Study: NCT05225233

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with sham tDCS (30 seconds ramp up/ramp down at the beginning of the session)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
Study: NCT05774496

Intervention type: OTHER
Intervention: Estimation of the occurrence of retinochoroiditis in women with congenital toxoplasmosis and previous retinochoroiditis lesions (recurrence) during pregnancy and postpartum.
Description: All fundus examinations completed during pregnancy and postpartum in women with congenital toxoplasmosis and previous retinochoroiditis lesions are going to be checked.
Study: NCT05769699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample
Study: NCT05857579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microblepharoexfoliation
Description: MBE was performed using the yokefellow instrument (Youke Electronic Corporation, Guangzhou, China), which contains a handpiece with a 1.80 mm diameter medical-grade diamond bur. Patients underwent MBE on the upper and lower lid margin of both eyes at 500 rpm until complete removal of accumulated biofilm debris, epithelial keratinization or capped meibomian glands. MBE was carried out only in the first combined treatment session.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intense pulse light
Description: IPL treatment was carried out with Thermaeye Plus (MDS Medical Technologies SL, Barcelona, Spain). The procedure began by applying an ultrasound gel (Carmado SL, Alicante, Spain) to the patient's periocular areas and upper eyelids. In the periocular areas, 6 light pulses were applied; 4 light pulses on the skin below the lower eyelid (with handpiece placed horizontally in the first pass and vertically in the second pass) and 2 light pulses on the canthal area (with handpiece placed vertically in first and second pass). The parameters were as follows: (1) Filter: 650 nm; (2) fluence: 9 j/cm2; (3) pulses: 2; (4) duration: 3 ms; (5) Delay: 20 ms; and (6) Cooling: 70%. In the upper eyelids, 4 light pulses were applied; 2 light pulses in the first and second pass, respectively. The parameters were as follows: (1) Filter: 650 nm; (2) Fluence: 5 j/cm2; (3) pulses: 1; (4) duration: 3 ms and (5) Cooling: 70%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian gland expression
Description: Finally, the MGX was performed on both upper and lower eyelids of each eye with a Collins forceps (Medi Instrument Inc, New York, USA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Home-based therapy
Description: Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home-based therapy
Description: Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
Study: NCT05009706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-care in Older frail Persons with Heart failure Intervention (SOPHI)
Description: Patients who are randomized to the Self Care group will receive oral and written information, advice and support on following activities: excercise (from physiotherapist), nutrition (dietician) and symptom management (nurse), based on patient´s individual needs and abilities. The Self Care group will perform the activities daily at home. Once a week, patients come to the hospital to exercise with the support of a physiotherapist. Once a week or every other week patients will meet (at hospital or by phone) the dietician and nurse to solve possible problems and to follow-up food/nutrition intake and symptoms/symptom management.
Study: NCT05645289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minodronate
Description: The minodronate group: The group will include thirty-six patients. Patients will take 1 mg of minodronate tablets orally with 200 mL of water in the morning. They can not lie flat for at least 30 minutes after taking the tablets, and they can not eat anything except water for at least 30 minutes after taking the tablets once a day for 12 weeks, for a total of 84 times.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: The alendronate group: A total of 36 patients will be treated with alendronate. Patients will be orally given 10-mg alendronate tablets daily and 200 mL of water in the morning. They could not lie down and eat anything except water for at least 30 minutes after taking the tablets. The treatment lasted for 12 weeks, corresponding to a total of 84 doses.
Study: NCT06286579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediately implant placement
Description: After atraumatic tooth extraction immediate implant placement with SOI surface and loading will be performed with temporary restoration. After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed
Description: After atraumatic tooth extraction, the extraction site will be left to heal for 4 months, just grafting with A-Oss and suture, according to a socket preservation procedure. Four month later, implant will be place and immediate loadind with temporary restoration will be performed.~After osseointegration (8 weeks), the temporary restoration will be modified according to the soft tissue management. After 3 to 4 months, a definitive digital or analog impression will be taken and later definitive restoration will be delivered
Study: NCT06031168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metformin gel coated implants
Description: Patients will be treated with 1% concentrated metformin gel coated hydrophilic dental implant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: uncoated hydrophilic dental implants
Description: Patients treated by uncoated implants
Study: NCT04705220

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MERIVA® Tablets
Description: The treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: The composition of placebo includes the same components of the treatment tablets, except for the active substance.
Study: NCT06289790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane (ESP) block
Description: Erector Spinae Plane (ESP) block for pain management in VATS procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine
Description: Lignocaine bolus and infusion for pain management in VATS procedure
Study: NCT05904743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afrezza
Description: Pharmaceutical form: powder Route of administration: inhalation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rapid-acting Insulin Analog
Description: Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin
Description: Pharmaceutical form: clear and colorless solution for injection Route of administration: subcutaneous
Study: NCT05331768

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: banding ligation plus terlipressin infusion
Description: Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: banding ligation plus terlipressin infusion
Description: Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
Study: NCT05731882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-SeaLA, CardioPulse PFA system
Description: First, pulmonary vein isolation(PVI) was performed with the novel hex spline PFA ablation catheter( CardioPulseTM PFA system, Hangzhou Dinova EP Technology Co., Ltd), then, pulsed field ablation and mechanical closure of the left atrial appendage were achieved by E-SeaLATM(Hangzhou Dinova EP Technology Co., Ltd) implantation.
Study: NCT05826522

Intervention type: OTHER
Intervention: observationnal
Description: cohort of blood collection and severals exams

Intervention type: OTHER
Intervention: observationnal
Description: cohort of blood collection and severals exams

Intervention type: OTHER
Intervention: observationnal
Description: cohort of blood collection and severals exams

Intervention type: OTHER
Intervention: observationnal
Description: cohort of blood collection and severals exams

Intervention type: OTHER
Intervention: observationnal
Description: cohort of blood collection and severals exams
Study: NCT05351060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom Fabricated Splint
Description: Participants will wear a customized splint on their affected hand(s)during the hours of sleep for the duration of the study.
Study: NCT06428383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat tablet
Description: Vericiguat tablet at doses 2.5 mg, 5 mg, or 10 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat suspension
Description: Vericiguat suspension at doses 0.2 mg/mL,~1 mg/mL taken orally once daily
Study: NCT06076473

Intervention type: DIAGNOSTIC_TEST
Intervention: Untargeted metabolomics
Description: Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Untargeted metabolomics
Description: Pilot untargeted plasma metabolomics aiming to identify novel biomarkers for PA diagnosis and subtyping, which could be compared against existing biomarkers and taken forward to larger future studies.
Study: NCT06405516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous blood cell salvage with in-house device
Description: In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous cell salvage with i-Sep SAME device
Description: In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.